BCMA-TGF-beta insensitive armored CAR T cells
Term · Oncology and biomedicine · MLC-T-ONC-011916
A preparation of human T lymphocytes genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and armored to be insensitive to the immunosuppressive cytokine transforming growth factor-beta (TGF-beta), with potential immunostimulating and antineoplastic activities. Upon administration, BCMA-TGF-beta insensitive armored CAR T cells specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA, found on the surfaces of plasma cells and overexpressed on malignant plasma cells, plays a key role in plasma cell proliferation and survival. Though the nature of the TGF-beta armor has yet to be fully elucidated, it prevents the binding of TGF-beta to the CAR T-cells. TGF-beta negatively regulates T-cell proliferation and activation, contributes to the immunosuppressive nature of the tumor microenvironment (TME), and plays a key role in promoting tumor initiation, metastasis, and suppressing anti-tumor immunity.
| Identifier | MLC-T-ONC-011916 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-BCMA TGF-beta-insensitive CAR-T cells; anti-BCMA-CAR-expressing TGF-beta Insensitive T cells; BCMA TGFb-resistant CAR-T cells |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011916",
"term": "BCMA-TGF-beta insensitive armored CAR T cells",
"field": "Oncology and biomedicine",
"definition": "A preparation of human T lymphocytes genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and armored to be insensitive to the immunosuppressive cytokine transforming growth factor-beta (TGF-beta), with potential immunostimulating and antineoplastic activities. Upon administration, BCMA-TGF-beta insensitive armored CAR T cells specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA, found on the surfaces of plasma cells and overexpressed on malignant plasma cells, plays a key role in plasma cell proliferation and survival. Though the nature of the TGF-beta armor has yet to be fully elucidated, it prevents the binding of TGF-beta to the CAR T-cells. TGF-beta negatively regulates T-cell proliferation and activation, contributes to the immunosuppressive nature of the tumor microenvironment (TME), and plays a key role in promoting tumor initiation, metastasis, and suppressing anti-tumor immunity.",
"synonyms": [
"anti-BCMA TGF-beta-insensitive CAR-T cells",
"anti-BCMA-CAR-expressing TGF-beta Insensitive T cells",
"BCMA TGFb-resistant CAR-T cells"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/bcma-tgf-beta-insensitive-armored-car-t-cells/"
}
Record 3,360 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.